| CAS: | 248282-01-1 | ||||||||||
| 分子式: | C21H22N2O3 | ||||||||||
| 分子量: | 350.41 | ||||||||||
| 英文名称: |
| ||||||||||
| 用途: | Paquinimod 是一种 S100A9 抑制剂,阻止 S100A9 与 TLR-4 结合。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||
| P880045 | MACKLIN | Paquinimod | ≥98% | 378元/5mg; 599元/10mg; 1001元/25mg; 2560元/100mg; 4351元/250mg; | 咨询 | ||||||||||||||||||||||||||||
储存:2-8℃ 状态:白色到灰白色固体 | |||||||||||||||||||||||||||||||||
| SML2883 | Sigma-Aldrich | Paquinimod | ≥98% (HPLC) | 1042.98元/5 MG; 4208.37元/25 MG; | 咨询 | ||||||||||||||||||||||||||||
产品说明 生化/生理作用 Paquinimod (ABR-215757) is an orally active quinoline-3-carboxamide (Q substance) class immunomodulator that targets S100A9 (Calgranulin B; MRP14) via direct binding and blocks its interaction with receptor for advanced glycation end products (RAGE) and Toll-like receptor 4 (IC50 = 26 μM & 23 μM against 100 nM hS100A9 from binding immobilized hRAGE & hTLR4/MD2, respectively). Paquinimod in vivo efficacy is demonstrated in murine models of autoimmune/inflammatory diseases, including liver fibrosis, collagen-induced osteoarthritis, peritonitis, EAE, type 1 diabetes, lupus (0.04-25 mg/kg/day p.o.), and atherosclerosis (10 mg/kg i.p.). 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||